Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Five patients with end-stage kidney disease received genetically engineered pig kidneys through an expanded access program, with three maintaining kidney function for over eight months without dialysis and two subsequently transitioning to human donor kidneys. This represents the first documented cases of xenotransplantation functioning as genuine bridge therapy, extending dialysis-free survival while preserving access to human organ transplantation.
Function Health has launched a secure connector allowing users to feed personalized lab results and clinical notes into mainstream AI chatbots—ChatGPT, Claude, and Perplexity—enabling AI to provide answers grounded in individual biomarkers rather than population averages. This addresses a critical gap: AI health guidance has been generic and contextless, while over 80% of Function's members show at least one biomarker outside optimal ranges that warrant investigation and intervention.
Scribe Therapeutics has initiated human trials of STX-1150, a gene therapy designed to silence PCSK9 and reduce LDL cholesterol. Preclinical data in primates demonstrated sustained LDL reductions exceeding 50% at therapeutic doses, with potential implications for cardiovascular risk reduction in patients with familial hypercholesterolemia or statin-resistant disease.
Mito Health, a direct-to-consumer diagnostics platform, has administered over one million tests across seven preventive categories including genomic sequencing, microbiome analysis, advanced imaging, and liquid biopsy screening. The expansion reflects growing demand for accessible, transparent-pricing diagnostic services that operate outside traditional insurance infrastructure.
Annovis Bio exceeded enrollment targets for its Phase 3 trial of buntanetap, recruiting 850 patients against a goal of 760 for early Alzheimer's disease. The achievement demonstrates patient demand for novel therapeutics, though the drug's efficacy and regulatory approval remain unproven and contingent on data expected in early 2027.
LifespanningRx released the Peptide Explorer, a structured digital questionnaire that maps health goals across ten domains and flags potential peptide therapy candidates for clinician review. The tool screens responses against safety criteria before recommending further evaluation, positioning peptide therapy within a clinician-supervised framework rather than direct-to-consumer access.
Minicircle, a gene therapy company, advanced to the XPRIZE Healthspan finals with a non-viral circular DNA platform designed to address multiple aging phenotypes simultaneously—muscle decline, neuroinflammation, mitochondrial dysfunction, and immune dysregulation—in adults aged 50 to 80. The $1 million award will fund a placebo-controlled human trial to measure rejuvenation endpoints, representing a shift toward measurable, multisystem interventions in aging.
Adenine base editing delivered via AAV9 achieved partial correction of the LMNA mutation in HGPS mice, rescuing structural bone defects and normalizing gene expression when administered at two weeks of age. This demonstrates that in vivo base editing can address monogenic bone disorders and establishes timing-dependent efficacy for genetic correction strategies.
GLP-1 receptor agonists extended median lifespan in mice by approximately 14% independent of weight loss, suggesting mechanistic pathways beyond metabolic reduction. This finding positions GLP-1 signaling as a potential longevity intervention with relevance to aging biology beyond diabetes and obesity management.
Researchers and clinicians convened to establish a clinical roadmap for senescence research, identifying priorities including functional classification of senescent states, standardized biomarkers, and precision medicine frameworks. This represents the first coordinated effort to bridge cellular senescence findings into clinical practice and policy.
The Longevity Science Foundation has extended its Invested in Her campaign deadline to October 1, 2026, targeting $250,000 to fund early-stage research into ovarian aging and menopause—a critical gap in women's health science that receives less than 1% of NIH funding despite its systemic impact on cardiometabolic, neurological, and skeletal health across the lifespan.
THPharm is using AI to identify additional therapeutic applications for THP-001, a metabolic drug currently in Phase 3 trials, by analyzing how the compound affects gene expression and biological pathways. This reverse-engineering approach reduces development risk and cost by leveraging existing safety data rather than starting clinical validation from scratch.